Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

The aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high‐performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half‐life (t_1/2λz) 1.85 and 3.31 hr, area under the plasma concentration–time curve (AUC_0–∞) 15.74 and 174 hr * μg/ml, volume of distribution at steady‐state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr^?1 kg^?1, respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 μg/ml, time to reach peak concentration 1 and 1.5 hr, t_1/2λz 4.74 and 3.62 hr, and AUC_0–∞ 22.75 and 147 hr * μg/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12‐hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of ≤0.5 and ≤4 μg/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.     

单诺沙星在蛋雏鸡体内的药物动力学及生物利用度的研究

选用 4～ 5周龄健康蛋雏鸡 12 5只 ,按 5 mg/kg的剂量进行静脉注射和内服单诺沙星的药动学研究及生物利用研究。高效液相色谱内标法测定血浆中药物浓度 ,MCPKP药动学程序处理药时数据。静脉注射和内服给药后血药浓度—时间数据分别符合无吸收因素二室开放式模型和一级吸收一室开放式模型。静脉注射给药的主要药动学参数为 :t1 /2α=0 .3313h、t1 /2β= 5 .994 0 h、Vd=7.5 2 4 6 L/kg、AU C=5 .6 916 μg/m l· h、CLB=0 .8935 L/kg· h。内服给药后主要药动学参数为 :t1 /2 Ka=0 .30 2 9h、t1 /2 K=6 .5 12 8h、tmax=1.2 10 0 h、Cmax=0 .5 15 9μg/m l、AU C=5 .132 9μg/ml· h。生物利用度为 90 .18%。     

Pharmacokinetics and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous,intramuscular, subcutaneous,and oral administrations

The aim of the present study was to determine the pharmacokinetics (PKs) and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations at a dose of 10 mg/kg. A total of eight clinically healthy chukar partridges weighing 480 ± 45 g were used for the investigation. The study was performed in a crossover design (2 × 2 × 2 × 2) with a 15‐day washout period between two administrations in four periods. The plasma concentrations of danofloxacin were determined using reversed‐phase high‐performance liquid chromatography. Noncompartmental PK parameters were also estimated. No local or systemic adverse drug effects were observed in any of the chukar partridges. The mean elimination half‐life ranged between 8.18 and 12.08 hr and differed statistically among administration routes. The mean peak plasma concentrations of danofloxacin following IM, SC, and PO administrations were 8.05, 9.58, and 3.39 μg/ml at 0.5, 1, and 4 hr, respectively. Following IM, SC, and PO administrations, the mean bioavailability was 86.33%, 134.40%, and 47.62%, respectively. The mean total clearance and volume of distribution at steady‐state following IV administration were 0.13 L hr^?1 kg^?1 and 0.96 L/kg, respectively. These data, including favorable PKs and the absence of adverse drug effects, suggest that danofloxacin is a useful antibiotic in chukar partridges.     

乳酸恩诺沙星可溶性粉在鸡体内的药动学研究

24只苏禽黄羽肉鸡随机分成2组,分别按10 mg/kg体重剂量静注和内服乳酸恩诺沙星。测定乳酸恩诺沙星在鸡体内的药动学参数和生物利用度。恩诺沙星血药浓度数据用3p87计算机软件处理。静注乳酸恩诺沙星后的血药浓度-时间数据符合二室开放模型,主要动力学参数:t1/2α(0.45±0.16)h,t1/2β(7.02±1.42)h,CL(s)(0.38±0.10)L/kg/h,AUC(23.69±5.56)(mg/L)×h。内服乳酸恩诺沙星的血药浓度时间数据,符合有吸收因素二室模型,主要动力学参数:t1/2ka(0.60±0.01)h,t1/2ke(8.25±1.73)h,tpeak(2.44±0.17)h,Cmax(1.44±0.30)mg/L,AUC(20.74±3.80)(mg/L)×h,F 87.54%。结果表明,乳酸恩诺沙星可溶性粉在鸡体内具有吸收快、分布广、消除较慢以及内服生物利用度高的药动学特征。     

恩诺沙星在猪体内的生物利用度及药物动力学研究

选用２１头健康杂种猪，随机分为３组，对静注、肌注及内服恩诺沙星（２．５ｍｇ／ｋｇ）的生物利用度和药物动力学进行了研究。用乙腈提取血浆中的药物，反相高效液相色谱法测定血浆中恩诺沙星及其主要代谢产物环丙沙星的浓度。所得血药浓药－时间数据用ＭＣＰＫＰ计算机程序处理。静注给药的药时数据适合二室开放模型，主要药物动力学参数：ｔ１／２ａ０．４８±０．２４ｈ；ｔ１／２ａ３．４５±０．８５ｈ；ｔ１／２Ｋ１０２．０     

Pharmacokinetics of a single intramuscular injection of cefquinome in buffalo calves

The objective of this study was to investigate the pharmacokinetics of cefquinome following single intramuscular (IM) administration in six healthy male buffalo calves. Cefquinome was administered intramuscularly (2 mg/kg bodyweight) and blood samples were collected prior to drug administration and up to 24 hr after injection. No adverse effects or changes were observed after the IM injection of cefquinome. Plasma concentrations of cefquinome were determined by high‐performance liquid chromatography. The disposition of plasma cefquinome is characterized by a mono‐compartmental open model. The pharmacokinetic parameters after IM administration (mean ± SE) were C_max 6.93 ± 0.58 μg/ml, T_max 0.5 hr, t_½kα 0.16 ± 0.05 hr, t_½β 3.73 ± 0.10 hr, and AUC 28.40 ± 1.30 μg hr/ml after IM administration. A dosage regimen of 2 mg/kg bodyweight at 24‐hr interval following IM injection of cefquinome would maintain the plasma levels required to be effective against the bacterial pathogens with MIC values ≤0.39 μg/ml. The suggested dosage regimen of cefquinome has to be validated in the disease models before recommending for clinical use in buffalo calves.     

恩诺沙星及其代谢产物在奶山羊的药动学及乳中药物浓度

本试验研究单剂量静脉注射、肌肉注射和乳房灌注恩诺沙星（2.5mg/kg)在健康奶山羊的药动学及乳中药物浓度。采用HPLC法测定血浆和乳中恩诺沙星及其代谢产物环丙沙星的浓度，用统计矩原理处理血浆中药物浓度－时间数据，计算非房室模型的药动学参数。静脉注射、肌肉注射和乳房灌注恩诺沙星的t1/2β分别为1.32、1．55、0．99h;AUC为1．06、3．04、2．66mghL^-1；恩诺沙星的代谢分数为35．01％、44．06％、45．73％；环丙沙星的t1/2β为1．81、2．94、2．32h。乳中的药物浓度高于同期血中药物浓度，且乳中环丙沙星浓度高于恩诺沙星浓度并维持更长的时间。     

Pharmacokinetics and dosage regimen of cefotaxime in cross-bred calves following single intramuscular administration

The pharmacokinetics, penetration into erythrocytes and plasma protein binding of cefotaxime were investigated in cross-bred calves. Following a single intramuscular dose of cefotaxime (10 mg/kg), the absorption half-life and elimination half-life were 0.13±0.03 h and 2.97±0.72 h, respectively. The apparent volume of distribution and total body clearance were 3.28±0.72 L/kg and 0.78±0.08 L/kg per h, respectively. The extent of penetration into erythrocytes was 24–40% of the total blood concentration. Cefotaxime was bound to plasma proteins of calves to the extent of 25.5–33.6%. A satisfactory intramuscular dosage regimen for cefotaxime in calves would be 11 mg/kg followed by 10 mg/kg at 7 h intervals.Abbreviations ATCC American type cell culture - MIC minimum inhibitory concentration - PCV packed cell volume     

达氟沙星脂质体在蛋雏鸡体内的组织动力学及靶向性研究

将260只28日龄试验鸡(体质量215~230 g)随机分成5组:健康对照组20只,甲磺酸达氟沙星溶液静注给药组和内服给药组、甲磺酸达氟沙星脂质体静注给药组和内服给药组,每组60只。以5 mg/kg体质量剂量分别采用静脉注射和内服2种给药途径给予健康蛋雏鸡甲磺酸达氟沙星溶液和脂质体混悬液,于给药后0.167、0.333、0.5、0.75、1、1.5、2、4、6、9、12、24 h各剖杀5只鸡,取血液、肝脏、肾脏、肺脏和肌肉样品。采用反相HPLC色谱内标法测定各组织中达氟沙星浓度。应用MCPKP分析软件处理血浆药物浓度-时间数据,比较2种剂型的组织药动学参数。结果显示,与溶液组相比,甲磺酸达氟沙星脂质体组肝脏、肺脏中的药物分布明显提高,肾脏中的分布降低;通过相对摄取率、靶向效率和峰浓度比3个靶向指标的对比,脂质体组明显提高了肺部靶向性,且在肺部有一定的缓释作用。     

Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in freshwater crocodiles (Crocodylus siamensis) after intravenous and intramuscular administration

To the best of the authors’ knowledge, pharmacokinetic information to establish suitable therapeutic plans for freshwater crocodiles is limited. Therefore, the purpose of this study was to clarify the pharmacokinetic characteristics of enrofloxacin (ENR) in freshwater crocodiles, Crocodylus siamensis, following single intravenous and intramuscular administration at a dosage of 5 mg/kg body weight (b.w.). Blood samples were collected at assigned times up to 168 hr. The plasma concentrations of ENR and its metabolite ciprofloxacin (CIP) were measured by liquid chromatography tandem–mass spectrometry. The concentrations of ENR and CIP in the plasma were quantified up to 144 hr after both the administrations. The half-life was long (43–44 hr) and similar after both administrations. The absolute i.m. bioavailability was 82.65% and the binding percentage of ENR to plasma protein ranged from 9% to 18% with an average of 10.6%. Percentage of CIP (plasma concentrations) was 15.9% and 19.9% after i.v. and i.m. administration, respectively. Based on the pharmacokinetic data, susceptibility break point and PK-PD indexes, i.m. single administration of ENR at a dosage of 5 mg/kg b.w. might be appropriate for treatment of susceptible bacteria (MIC > 1 μg/mL) in freshwater crocodiles, C. siamensis.     

Pharmacokinetics and tissue residues of enrofloxacin in the largemouth bass (Micropterus salmoides) after oral administration

The study was carried out to evaluate the pharmacokinetic disposition of enrofloxacin (ENF) with a single dose of 20 mg/kg after oral administration in largemouth bass (Micropterus salmoides) at 28°C. The concentrations of ENF and of its metabolite ciprofloxacin (CIP) in plasma, liver, and muscle plus skin in natural proportions were determined using HPLC. The concentration–time data for ENF in plasma were best described by a two-compartment open model. After oral administration, the maximum ENF concentration (C_max) of 10.99 μg/ml was obtained at 0.60 hr. The absorption half-life (T_1/2Ka) of ENF was calculated to be 0.07 hr whereas the elimination half-life (T_1/2β) of the drug was 90.79 hr. The estimates of area under the plasma concentration–time curve (AUC) and apparent volume of distribution (Vd/F) were 1,185.73 μg hr/ml and 2.21 L/kg, respectively. ENF residues were slowly depleted from the liver and muscle plus skin of largemouth bass with the T_1/2β of 124.73 and 115.14 hr, respectively. Very low levels of ciprofloxacin were detected in the plasma and tissues. A withdrawal time of 24 days was necessary to ensure that the residues of ENF + CIP in muscle plus skin were less than the maximal residue limit (MRL) of 100 μg/kg established by the European Union.     

Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves

The pharmacokinetics and urinary excretion following single intramuscular administration of levofloxacin at a dose of 4 mg/kg was investigated in seven male cross bred calves. Appreciable plasma concentration of levofloxacin (0.38 ± 0.06 µg/ml) was detected at 1 min after injection and the peak plasma level of 3.07 ± 0.08 µg/ml was observed at 1 h. The drug level above MIC₉₀ in plasma was detected up to 12 h after administration. Rapid absorption of the drug was also evident by the high value of the absorption rate constant (2.14 ± 0.24 /h). The overall systemic bioavailability of levofloxacin, after intramuscular administration, was 56.6 ± 12.4%. The high value of AUC (7.66 ± 0.72 mg . h/ml) reflected the vast area of body covered by drug concentration. Extensive distribution of the drug into various body fluids and tissues was noted by the high value of Vd_area (1.02 ± 0.05 l/kg). The high ratio of AUC/MIC (76.6 ± 7.25) obtained in this study indicated excellent clinical and bacteriological efficacy of levofloxacin in calves. The elimination half-life and MRT were 3.67 ± 0.4 h and 5.57 ± 0.51 h, respectively. The total body clearance (Cl_B) was 204.9 ± 22.6 ml/kg/h. On the basis of the pharmacokinetic parameters, a suitable intramuscular dosage regimen for levofloxacin in calves would be 1.5 mg/kg repeated at 12 h intervals.     

单诺沙星（Danofloxacin）在雏鸡体的组织动力学及残留

以高效液相色谱法为定量手段 ,研究了单诺沙星 (danofloxacin)在雏鸡体内的组织动力学特征 ,并采用回归分析法研究了血药浓度与组织药物浓度间的相关性。6 0只雏鸡口服单诺沙星 (5 m g/ kg)后 ,血浆的药时数据符合一级吸收二室模型。肝脏、肾脏、心脏、肺脏的药时数据符合一级吸收三项指数方程 ;心脏的药时数据符合一级吸收二项指数方程。血浆、肝脏、肾脏、心脏、肺脏及肌肉的主要动力学参数是 :t1 /2 ka分别为 0 .2 42 8、0 .35 2 4、0 .35 41、0 .2 6 43、0 .3377、0 .2 5 36 h、t1 /2α分别为 0 .8917、1.12 12、0 .7189、1.6 142、0 .44 37h(缺肌肉的 t1 /2α) ,t1 /2β分别为 8.7936、3.6 0 2 5、4.45 70、10 .2 940、4.32 83、5 .95 78h,Tp分别为 0 .9377、1.0 6 6 5、0 .936 2、0 .9993、0 .996 2、1.4381h,Cmax分别为0 .5 487、 2 .8419、 2 .42 95、 0 .2 6 6 8、 1.70 42、 0 .2 72 6 m g/ L ,AUC分别为 3.0 5 2 3、 13.5 86 0、 10 .4180、 2 .15 2 1、9.6 888、2 .715 7mg/ (L· h) ,Tcp分别为 12 .6 130、18.0 730、18.8790、8.0 5 5 7、19.6 930、13.86 0 0 h。研究结果表明 ,组织中的药物浓度以肝脏、肾脏最高 ,其次是肺脏 ,均显著高于血浆中的药物浓度 ,心脏、肌肉中的浓度最低 ,血浆     

Pharmacokinetics of enrofloxacin in newborn and one-week-old calves

The pharmacokinetic behaviour of enrofloxacin was compared in four one-day-old and four one-week-old calves in order to find out if there were any age-related differences. Mean volume of distribution ( V _d(ss)) and clearance ( Cl ) were significantly smaller in newborn calves: V _d(ss) was 1.8 and 2.3 L/kg, while clearance was 0.19 and 0.39 L/kg.h in newborn and one-week-old calves, respectively. Mean elimination half-life ( t _1/2β) did not differ significantly in newborn and in one-week-old calves: mean t _1/2β was 6.6 h and 4.9 h, respectively. Enrofloxacin was metabolized to ciprofloxacin both by newborn and one-week-old calves, but the maximum concentration ( C _max) of ciprofloxacin was lower and the time when maximum concentration was reached ( t _max) later in newborn calves. We conclude that the dosage of enrofloxacin should be adjusted according to age when administered to very young calves.     

Comparison of pharmacokinetics of danofloxacin and enrofloxacin in calves challenged with Mannheimia haemolytica

OBJECTIVE: To compare concentrations of danofloxacin, enrofloxacin, and ciprofloxacin in plasma and respiratory tissues of calves treated after challenge with Mannheimia haemolytica. ANIMALS: 75 calves. PROCEDURE: 24 hours after challenge with M. haemolytica, 72 calves with clinical signs of respiratory tract disease were randomly assigned to 1 of 12 equal treatment groups.Three nonchallenged, nontreated calves formed a control group. Challenged calves were treated with danofloxacin (6 and 8 mg/kg, SC) and enrofloxacin (8 mg/kg, SC) once. At 1, 2, 6, and 12 hours after treatment, 6 calves from each treatment group were euthanatized. Antimicrobial drug concentrations were assayed in various specimens. Peak plasma concentration (Cmax)-to-minimum inhibitory concentration (MIC; Cmax-to-MIC) ratios and the area under the concentration versus time curve over a 12-hour period-to-MIC ratios (AUC(12h)-to-MIC) were calculat-ed. RESULTS: Danofloxacin and enrofloxacin had MICs of 0.03 microg/mL for the M. haemolytica challenge isolate. Danofloxacin administered at doses of 6 and 8 mg/kg resulted in numerically higher geometric mean concentrations of danofloxacin in plasma and all respiratory tissues than geometric mean concentrations of enrofloxacin after treatment with enrofloxacin. Geometric mean concentrations of enrofloxacin were numerically higher than geometric mean concentrations of ciprofloxacin metabolite in plasma and almost all respiratory tissues. Danofloxacin and enrofloxacin achieved Cmax-to-MIC ratios >10 and AUC(12h)-to-MIC ratios >125 hours. CONCLUSIONS AND CLINICAL RELEVANCE: When used to treat pneumonic pasteurellosis in calves, danofloxacin and enrofloxacin can be expected to deliver concentration-dependent bactericidal activity against M. haemolytica, the bacteria most commonly associated with bovine respiratory tract disease.     

恩诺沙星及其活性代谢物在鸡体内的药物动力学

为全面了解恩诺沙星在鸡体内的动力学过程与药效的关系进行了本研究。用反向高效液相色谱法测定鸡血浆中的药物质量浓度,所得恩诺沙星ｃｉ－ｔｉ数据用ＭＣＰＫＰ计算机程序处理,代谢物环丙沙星的ｃｉ－ｔｉ数据用代谢物动力学方法处理。静注恩诺沙星后的ｃｉ－ｔｉ数据符合二室开放模型,主要动力学参数：ｔ１／２α（０．２５±０．０４）ｈ,ｔ１／２β（５．２６±０．８１）ｈ,Ｖｄ（４．５３±１．０７）Ｌ／ｋｇ,ＣＬＢ（０．６１±０．１１）Ｌ／（ｋｇ·ｈ）,ＡＵＣ（１７．３９±３．９２）ｍｇ／（Ｌ·ｈ）。内服恩诺沙星的ｃｉ－ｔｉ数据,符合有吸收因素二室模型,主要动力学参数ｔ１／２ｋａ（０．４４±０．１１）ｈ,ｔ１／２α（１．１５±０．３８）ｈ,ｔ１／２β（９．１４±１．４５）ｈ,ＡＵＣ（１２．４８±２．３６）ｍｇ／（Ｌ·ｈ）,ｔｍａｘ（１．７７±０．２１）ｈ,Ｃｍａｘ（１．４４±０．３１）ｍｇ／Ｌ,Ｆ７２．１８％。试验结果表明,鸡静注与内服恩诺沙星后,代谢物环丙沙星的生成及消除缓慢、分布广泛,是影响恩诺沙星疗效的重要因素。     

Population pharmacokinetics for danofloxacin in the intestinal contents of healthy and infected chickens

Avian pathogenic Escherichia coli could cause localized and systemic infection in the poultry, and danofloxacin is usually used to treat avian colibacillosis through oral administration. To promote prudent use of danofloxacin and reduce the emergence of drug‐resistant E. coli strains, it is necessary to understand the population pharmacokinetics (PopPK) of danofloxacin in chicken intestines. In this study, reversed‐phase high performance liquid chromatography (HPLC) with fluorescence detection was used to detect the concentrations of danofloxacin in the contents of duodenum, jejunum, and ileum of the healthy and infected chickens after single oral administration (5 mg/kg body weight). Then, the PopPK of danofloxacin in intestines were analyzed using NONMEM software. As a result, a two‐compartment PK model best described the time‐concentration profile of duodenal, jejunal, and ileal contents. Interestingly, absorption rate (K_a), distribution volume (V), and clearance (CL) for danofloxacin from duodenal, jejunal to ileal contents were sequentially decreased in the healthy chickens. However, the trend of K_a, V, and CL of danofloxacin was changed dramatically in the intestine of infected chickens. K_a and V of danofloxacin in the jejunum were higher than in the ileum and duodenum. Compared with healthy chickens, K_a and V of danofloxacin in the duodenum decreased significantly, while increased in jejunum, respectively. It has been noted that K_a decreased and V increased in the ileum of infected chickens. Besides, CL in the duodenum, jejunum, and ileum of infected chickens was, respectively, lower than those of healthy chickens. Interestingly, the relative bioavailability (F) of danofloxacin in the ileum was relatively higher in both healthy and infected chickens. In addition, F in the duodenal, jejunal, and ileal contents of infected chickens was respectively higher than healthy chickens. In summary, the PopPK for danofloxacin in infected chicken intestines was quite different from healthy chickens. The absorption, distribution, and clearance of danofloxacin in healthy chickens decreased from duodenum to jejunum and to ileum. Moreover, the pharmacokinetic characteristics in the intestine of infected chickens changed significantly, and the pharmacokinetic characteristics in the ileum can be used as a representative of all intestinal segments.     

旋光法测定甲磺酸达氟沙星的含量

采用旋光法测定甲磺酸达氟沙星的含量,结果表明,在6～14 mg/mL浓度范围内,甲磺酸达氟沙星的旋光度与浓度呈良好的线性关系(r=0.999 8).与电位滴定法相比,本法具有简单、快速、易操作等优点.     

恩诺沙星微囊在猪体内的药动学及生物利用度研究

为了比较恩诺沙星微囊和原粉在猪体内的药动学特征及生物利用度,试验采用高效液相色谱法(HPLC),将10头健康猪分2组采用正交试验,经灌胃给药后采血、甲醇提取和HPLC分析,所得药时数据用MCPKP计算机程序处理。恩诺沙星微囊和原粉经口服给药后在猪体内的药时数据均符合一级吸收一室模型,主要药动学参数分别为:t1/2Ka1.73 h±0.93 h和0.36 h±0.31 h(P0.01);Tmax5.69 h±1.68 h和2.04 h±1.06 h(P0.01);t1/2Ke16.53 h±5.23 h和10.17 h±1.87 h(P0.01);Cmax1.71μg/mL±0.47μg/mL和2.51μg/mL±0.45μg/mL(P0.01);AUC为每小时51.98μg/mL±16.08μg/mL和40.58μg/mL±6.40μg/mL;微囊的相对生物利用度为128%。说明恩诺沙星微囊口服给药吸收较慢但完全,达峰时间较长,消除缓慢。